Janux Therapeutics Appoints Ron Barrett, Ph.D., And Alana McNulty To Board Of Directors - NewsBreak

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the additions of Ronald W. Barrett, Ph.D., and Alana McNulty as members of the Company's Board of Directors. Dr. Barrett is a scientist entrepreneur with more than 30 years of experience in the biopharmaceutical industry, founding and leading biopharmaceutical companies, including advancing research that has led to FDA approval of three drugs. Ms. McNulty has more than 30 years of experience in finance and business development for private and publicly traded biopharmaceutical companies.